地塞米松联合孟鲁司特钠治疗儿童过敏性紫癜临床观察
|
摘要
目的观察地塞米松联合孟鲁司特钠治疗儿童过敏性紫癜(HSP)的疗效。方法选取医院2015年至2017年收治的HSP患儿62例,随机分为观察组(地塞米松+孟鲁司特钠治疗)与对照组(地塞米松治疗),各31例。结果观察组中有1例脱落,其余患儿皮疹消退时间、关节症状缓解时间、腹痛缓解时间、尿常规异常恢复时间均显著短于对照组(P <0. 05);观察组治疗有效率为93. 33%,显著高于对照组的67. 74%(P <0. 05);治疗2周后,两组患儿血清C-反应蛋白(CRP)、免疫球蛋白A(IgA)、白细胞介素4(IL-4)水平均显著降低(P <0. 05),且观察组显著低于对照组(P <0. 05);治疗3个月后,两组患儿β2微球蛋白(β2-MG)、转铁蛋白(TRF)水平均显著降低(P <0. 05),且观察组显著低于对照组(P <0. 05);观察组不良反应发生率为10. 00%,显著低于对照组的35. 48%(P <0. 05)。结论地塞米松联合孟鲁司特钠可有效缓解HSP的临床症状,保护肾脏,提高治疗有效率,且用药安全性高。
Objective To observe the clinical effect of dexamethasone combined with montelukast sodium in the treatment of childrenpatients with Henoch-Schonlein purpura( HSP). Methods Totally 62 children patients with HSP admitted to our hospital from 2015 to 2017 were randomly divided into the observation group( dexamethasone combined with montelukast sodium) and the control group( dexamethasone), 31 cases in each group. Results In the observation group, 1 case was shed and the other cases were involved inthe entire study, and the rash disappearance time, joint symptom remission time, abdominal pain remission time and recovery time ofabnormal urine routine in the observation group were significantly shorter than those in the control group( P < 0. 05). The effectiverate of treatment in the observation group was 93. 33%,which was significantly higher than 67. 74% in the control group( P < 0. 05).After 2 weeks of treatment,the levels of serum C-reactive protein( CRP),immunoglobulin-A( IgA) and interleukin-4( IL-4) in thetwo groups were significantly decreased( P < 0. 05), and those in the observation group were significantly lower than those in thecontrol group( P < 0. 05). After 3 months of treatment, the levels of β2-microglobulin( β2-MG) and transferrin( TRF) in the twogroups were significantly decreased( P < 0. 05), and those in the observation group were significantly lower than those in the controlgroup( P < 0. 05). The incidence rate of adverse reactions in the observation group was 10. 00%, which was significantly lower than35. 48% in the control group( P < 0. 05). Conclusion Dexamethasone combined with montelukast sodium can effectively relieve theclinical symptoms of children patients with HSP, protect their kidneys, and improve the effective rate of treatment, and it has highmedication safety.
Objective To observe the clinical effect of dexamethasone combined with montelukast sodium in the treatment of childrenpatients with Henoch-Schonlein purpura( HSP). Methods Totally 62 children patients with HSP admitted to our hospital from 2015 to 2017 were randomly divided into the observation group( dexamethasone combined with montelukast sodium) and the control group( dexamethasone), 31 cases in each group. Results In the observation group, 1 case was shed and the other cases were involved inthe entire study, and the rash disappearance time, joint symptom remission time, abdominal pain remission time and recovery time ofabnormal urine routine in the observation group were significantly shorter than those in the control group( P < 0. 05). The effectiverate of treatment in the observation group was 93. 33%,which was significantly higher than 67. 74% in the control group( P < 0. 05).After 2 weeks of treatment,the levels of serum C-reactive protein( CRP),immunoglobulin-A( IgA) and interleukin-4( IL-4) in thetwo groups were significantly decreased( P < 0. 05), and those in the observation group were significantly lower than those in thecontrol group( P < 0. 05). After 3 months of treatment, the levels of β2-microglobulin( β2-MG) and transferrin( TRF) in the twogroups were significantly decreased( P < 0. 05), and those in the observation group were significantly lower than those in the controlgroup( P < 0. 05). The incidence rate of adverse reactions in the observation group was 10. 00%, which was significantly lower than35. 48% in the control group( P < 0. 05). Conclusion Dexamethasone combined with montelukast sodium can effectively relieve theclinical symptoms of children patients with HSP, protect their kidneys, and improve the effective rate of treatment, and it has highmedication safety.
引文
[1]肖李艳,潘险峰,陈勇.过敏性紫癜复发及肾损害的相关危险因素分析[J].海南医学,2016,27(4):626-628.
[2]晏云,马健.糖皮质激素递减疗法对小儿重症过敏性紫癜的疗效观察[J].医学综述,2016,22(7):1451-1454.
[3]丁云峰,李志辉,段翠蓉,等.孟鲁司特钠治疗30例小儿过敏性紫癜的效果分析[J].医学临床研究,2017,34(1):164-165.
[4] OZEN S,RUPERTO N,DILLON MJ,et al. EULAR/PReS en-dorsed consensus criteria for the classification of childhood vas-culitides[J]. Ann Rheum Dis,2006,65(7):936-941.
[5]魏明通,胡乃中.腹型过敏性紫癜的临床及内镜特点分析[J].安徽医学,2016,37(5):512-516.
[6]李梅爱,谭晓明,邝婉仪,等.尿中微量蛋白和尿N-乙酰-β-D-氨基葡萄糖苷酶的检测对儿童过敏性紫癜肾炎的意义[J].中国卫生检验杂志,2016,26(4):534-535.
[7]刘红娟,刘海鹏,张晨宇,等.过敏性紫癜患儿早期肾损伤生物标志物特征分析[J].安徽医学,2017,38(6):723-725.
[8]刘霞,李雄,郭睿,等. 30例腹型过敏性紫癜治疗体会[J].中国中西医结合皮肤性病学杂志,2016,15(5):295-296.
[9]温丽,房倩,刘淑荣,等.低分子肝素联合小剂量糖皮质激素预防儿童过敏性紫癜肾损害的疗效观察[J].河北医药,2018,40(1):114-116.
[10]柯文玲,吴萍,韦丹.孟鲁司特钠联合糖皮质激素治疗过敏性紫癜的效果[J].中国妇幼健康研究,2017,28(12):1648-1650.
[11]张小霞,吴俭,冯静.复方甘草酸苷对过敏性紫癜患儿尿白三烯E4的影响[J].江西医药,2016,51(11):1244-1245.
[12]黄琰,字友梅,张媛,等.孟鲁司特治疗过敏性紫癜的临床有效性分析与研究[J].海峡药学,2017,29(2):161-162.
[13]赵春利,杨丹丹,高玉娟,等.血浆凝血因子ⅩⅢ与过敏性紫癜患者腹痛的相关性研究[J].血栓与止血学,2016,22(2):154-156.
[14]雷亚星,孙霞.儿童紫癜性肾炎发病机制研究进展及诊治现状[J].中国基层医药,2017,24(16):2544-2547.
[2]晏云,马健.糖皮质激素递减疗法对小儿重症过敏性紫癜的疗效观察[J].医学综述,2016,22(7):1451-1454.
[3]丁云峰,李志辉,段翠蓉,等.孟鲁司特钠治疗30例小儿过敏性紫癜的效果分析[J].医学临床研究,2017,34(1):164-165.
[4] OZEN S,RUPERTO N,DILLON MJ,et al. EULAR/PReS en-dorsed consensus criteria for the classification of childhood vas-culitides[J]. Ann Rheum Dis,2006,65(7):936-941.
[5]魏明通,胡乃中.腹型过敏性紫癜的临床及内镜特点分析[J].安徽医学,2016,37(5):512-516.
[6]李梅爱,谭晓明,邝婉仪,等.尿中微量蛋白和尿N-乙酰-β-D-氨基葡萄糖苷酶的检测对儿童过敏性紫癜肾炎的意义[J].中国卫生检验杂志,2016,26(4):534-535.
[7]刘红娟,刘海鹏,张晨宇,等.过敏性紫癜患儿早期肾损伤生物标志物特征分析[J].安徽医学,2017,38(6):723-725.
[8]刘霞,李雄,郭睿,等. 30例腹型过敏性紫癜治疗体会[J].中国中西医结合皮肤性病学杂志,2016,15(5):295-296.
[9]温丽,房倩,刘淑荣,等.低分子肝素联合小剂量糖皮质激素预防儿童过敏性紫癜肾损害的疗效观察[J].河北医药,2018,40(1):114-116.
[10]柯文玲,吴萍,韦丹.孟鲁司特钠联合糖皮质激素治疗过敏性紫癜的效果[J].中国妇幼健康研究,2017,28(12):1648-1650.
[11]张小霞,吴俭,冯静.复方甘草酸苷对过敏性紫癜患儿尿白三烯E4的影响[J].江西医药,2016,51(11):1244-1245.
[12]黄琰,字友梅,张媛,等.孟鲁司特治疗过敏性紫癜的临床有效性分析与研究[J].海峡药学,2017,29(2):161-162.
[13]赵春利,杨丹丹,高玉娟,等.血浆凝血因子ⅩⅢ与过敏性紫癜患者腹痛的相关性研究[J].血栓与止血学,2016,22(2):154-156.
[14]雷亚星,孙霞.儿童紫癜性肾炎发病机制研究进展及诊治现状[J].中国基层医药,2017,24(16):2544-2547.